Open AccessClinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity
Author(s) -
Guo Xiaoxiao,
Wang Hanping,
Zhou Jiaxin,
Li Yue,
Duan Lian,
Si Xiaoyan,
Zhang Li,
Fang Ligang,
Zhang Li
Publication year - 2020
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.13250
Subject(s) - medicine , cardiotoxicity , immune system , cytotoxic t cell , adverse effect , immune checkpoint , cancer , pd l1 , immunology , immunotherapy , oncology , chemotherapy , biochemistry , chemistry , in vitro
Immune checkpoint inhibitors (ICIs) targeting programmed death‐1 (PD‐1), its ligand (PD‐L1), and cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA4) have revolutionized cancer treatment by recovering the attack of T lymphocytes on the malignant cells. They have improved clinical outcomes dramatically in multiple types of advanced‐stage malignancies. Even though the tolerance and safety profiles are generally good, it has been widely reported that ICIs can cause severe or fatal immune‐related adverse events (irAEs), since the activated T lymphocytes are not specific for tumor cells. Cardiac irAEs appear to occur less frequently than irAEs in other organ systems but are notorious for high mortality. Here, we aim to identify and characterize the ICI‐associated cardiotoxicity and summarize the optional diagnosis and treatment strategies.